Setrusumab (BPS804)
For the potential treatment of Osteogenesis Imperfecta (“OI”), a rare genetic bone condition affecting children and adults.
Our pipeline currently consists of six clinical-stage product candidates.
We have already delivered three successful Phase 2 studies with a Phase 2 and Phase 1b/2 ongoing.
For the potential treatment of Osteogenesis Imperfecta (“OI”), a rare genetic bone condition affecting children and adults.
For the potential treatment of severe Alpha-1 Antitrypsin Deficiency-Related Lung Disease (AATD-LD) and Bronchiolitis Obliterans Syndrome (BOS).
For the potential treatment of patients with advanced or metastatic
solid tumors.
We have two additional programs with current partnering opportunities. Navicixizumab has been licensed out to OncXerna.
For the potential treatment of platinum-resistant ovarian cancer, partnered with OncXerna Therapeutics Inc. for further development.
For the potential treatment of acute exacerbations of chronic obstructive pulmonary disease (“AECOPD”).
For the potential treatment of male infertility associated with hypogonadotropic hypogonadism (“HH”).
Mereo BioPharma today announced updated clinical data from its open-label Phase 1b/2 Study of Etigilimab and Nivolumab in subjects with Select Locally Advanced or Metastatic Solid Tumors (ACTIVATE). The data will be presented in a poster session at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting on June 5, 2022. The Company also provided an update on its capital allocation and portfolio prioritization plan.
Mereo BioPharma today announced the presentation of interim clinical data from its Phase 1b/2 Study of Etigilimab and Nivolumab in Subjects with Select Locally Advanced or Metastatic Solid Tumors in a poster at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting taking place June 3 – 7, 2022 in Chicago IL.
Mereo BioPharma announces positive topline results from ASTRAEUS a Phase 2 trial of alvelestat in Alpha-1 Antitrypsin Deficiency- associated Emphysema.
Mereo BioPharma Group plc today announced it will host a conference call on Monday, May 9, 2022 at 10:30 a.m. ET to review top-line clinical data from its “ASTRAEUS” Phase 2 Study of Alvelestat in Alpha-1 Antitrypsin Deficiency-associated Emphysema.